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Abstract 
The availability of cell lines that are transfected with IL-4, IL-5 and IFN-y cytokine genes permits the prolonged 
in vivo delivery of functional cytokines in relatively large doses for the modulation of specific immune responses. 
Often the transfected cells are xenogeneic or allogeneic to the experimental nimal and have to be encapsulated in 
such a way that no cellular response by the host will be induced. Alginate has proven to be a simple matrix for 
encapsulating cells under mild conditions uitable for in vivo implantation. Encapsulated cells express the trans- 
fected IL-4 gene for at least 14 days after in vivo implantation and were shown to be functional during that period by 
modulating ongoing IgE responses. The application of adherent growing transfected cells permits dose-response 
titrations and provides an easy method for local and systemic ytokine delivery. Alternatively, hybridoma cells can be 
encapsulated and the secreted antibody monitored in the serum. It was found that no host immune response was 
triggered by alginate ncapsulated cells. The efficiency of treatment by encapsulated hybridoma cells was shown to 
be equivalent to that of injecting purified antibodies. 
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I. Introduction 
The immunoregulatory role of cytokines in im- 
mune responses is well established. A special 
interest has developed in the modulation of im- 
mune responses in experimental animal model 
systems by treatment with cytokine-neutralizing 
* Corresponding author. 
Abbreviations: IL, interleukin; IFN-y, interferon-y; mAb, 
monoclonal ntibody. 
monoclonal antibodies (mAb) or recombinant cy- 
tokines in vivo. This can be achieved by repeated 
injections of relatively large amounts (mg) of pu- 
rified mAb. Alternatively, multiple injections with 
several/xg of purified recombinant cytokines have 
to be given each day to induce a detectable 
effect. Major drawbacks to the application of 
these techniques are the large amounts of highly 
purified mAb or recombinant cytokines required, 
the need to use large scale purification proce- 
dures (with problems of yield, recovery, and en- 
dotoxin contamination of biologically active mate- 
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rial) and the short biological half life of most 
cytokines (minutes) in the circulation that neces- 
sitate multiple injections each day. 
IL-4 is obligatory for the induction of IgE 
synthesis as evidenced by its ability to induce the 
expression of E germline transcripts (Rothman et 
al., 1988; Yoshida et al., 1990), the inhibition of 
parasite-induced IgE responses by neutralizing 
antibodies against IL-4 (Finkelman et al., 1990), 
the absence of IgE responses in nematode-in- 
fected mice made IL-4 deficient by gene targeting 
(Kuhn et al., 1991) and the hyperproduction f 
IgE in IL-4 transgenic mice (Tepper et al., 1990; 
Muller et al., 1991). 
The availability of cell lines that are trans- 
fected with cytokine genes enables the in vivo 
application of functional cytokines in doses suffi- 
cient to modulate specific immune responses (Lee 
et al., 1986; Yokota et al., 1987; Karasuyama and 
Melchers, 1988). The implantation of these cell 
lines in vivo can be used as an alternative to 
cytokine transgenic animals without he potential 
drawbacks of developmental disturbances (Tepper 
et al., 1990; Muller et al., 1991). However, the 
transfected cells will often be xenogeneic or allo- 
geneic to the experimental nimal and have to be 
encapsulated in such a way that no cellular re- 
sponse by the host will be induced. Encapsulation 
in alginate provides a simple, suitable method for 
immobilizing viable cells under mild conditions 
for in vivo implantation (Kupchik et al., 1983; 
Kierstan and Coughlan, 1985; Bucke, 1987). 
This study describes the combination of adher- 
ent growing cytokine gene transfected cell lines 
and alginate ncapsulation for the in vivo modu- 
lation of the murine IgE response. 
V' according to the criteria of the Dutch Veteri- 
nary Inspection, as described in the law on ani- 
mal experiments. 
2.2. Antibodies 
Rat monoclonal IgG1 antibodies pecific for 
murine IL-4 (11Bll, Ohara and Paul, 1987), IL-5 
(TRFK 5, Schumacher tal., 1988) IFN-y (XMG 
1.2, Cherwinski et al., 1987) and E. coli/3-galac- 
tosidase (GL 113, used as an isotype control, 
Chatelain et al., 1992) were obtained by purifica- 
tion from the supernatants of stable hybridoma 
subclones grown in defined RPMI 1640 medium 
supplemented with pyruvate (0.1 M), L-glutamine 
(4 mM), antibiotics (100 U/ml penicillin and 50 
~g/ml streptomycin) and 1% (v/v) Nutridoma 
SP (Boehringer, Mannheim, Germany). The su- 
pernatants were concentrated approximately 20 
times by 10000 Da ultrafiltration (Amicon, Dan- 
vers, MA). The mAb were purified by saturated 
(20% w/v) sodium sulphate precipitation and 
dialysis into 50 mM sodium acetate buffer, pH 
4.9. After centrifugation at 10 000 rpm to remove 
precipitated albumin the antibodies were further 
purified by affinity chromatography on a 10 ml 
bed volume of Immunopure protein G (Pierce, 
Rockford, IL) using the same acetate buffer as 
loading buffer and 0.1 M glycine-HC1, pH 2.5 as 
elution buffer. After neutralization with 1 M Tris, 
the sample was dialysed into phosphate buffered 
saline, concentrated by ultracentrifugation a d 
filter sterilized through a 0.22 /zm Millex GV 
filter (Millipore, Bedford, MA). 
2.3. Cell lines 
2. Materials and methods 
2.1. Mice 
Female BALB/c, SJA/9 and SJL mice were 
bred and kept in our own colony and used at an 
age of 12-16 weeks. Animals were kept in light- 
cycled rooms and had free access to acidified 
water and food. The microbial status of the mice 
fulfilled the standard of 'specific pathogen free 
The above mentioned hybridoma cell lines 
were kind gifts of Dr. R.L. Coffman (DNAX 
Research Institute, Palo Alto, CA). Cultures of 
these hybridoma cell lines were also used for 
alginate encapsulation. Stable transformants of
the monkey CV1 cell line were obtained by trans- 
fecting the murine IL-4 or IL-5 gene and placing 
the gene under control of the SV40 promotor. 
Alternatively CHO-Ki cells were stably trans- 
fected with the murine IFN-y gene. All the trans- 
fected cell lines were kind gifts of Dr. N. Arai 
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(DNAX). These adherent cell lines were grown 
on Cytodex 3 beads (Pharmacia, Uppsala, Swe- 
den) in Dulbecco's modified medium (DMEM) 
containing 10% FCS, glutamine and antibiotics. 
Cells were kept in exponentional growth phase by 
splitting the cultures every 3 days. The TNP- 
specific mouse IgE secreting IgELA2 cell line was 
a kind gift of Dr. M. Wabl (Rudolph et al., 1981). 
2.4. Alginate encapsulation 
Cultured transfected cells grown on Cytodex 
beads were washed extensively with cold sterile 
saline and mixed with two parts of a sterile 1.2% 
alginate solution (FMC, Vallensbaek Strand, 
Denmark) that was warmed to room tempera- 
ture. The mixture was transferred into a syringe 
of suitable size equipped with a 23-27 gauge 
needle depending on the application (refer re- 
sults section). Next, the mixture was injected into 
a fresh solution of 80 mM CaC12 (prepared in 
water) at room temperature with continuous gen- 
tle mixing. The capsules were washed with cold 
saline and a 1 ml volume containing 2 x 106 cells 
(or other cell concentrations a indicated in the 
results ection) was injected intraperitoneally (i.p.) 
or subcutaneously (s.c.) as indicated. Alterna- 
tively, cultured hybridoma cells could also be 
encapsulated using 27 gauge needles. The cap- 
sules could be recovered for periods up to 18 
days after injection by peritoneal washing. The 
cells could be isolated by incubating the capsules 
for 5 min at 37°C with a 1% trypsin-EDTA mix- 
ture (Gibco, Grand Island, NY), thereby estab- 
lishing that these capsules remained intact in the 
mouse and that the encapsulated cells were vi- 
able for this period in vivo and were still able to 
produce cytokines in vitro after their recovery. 
2.5. Assays 
Mice were immunized with 10 /zg TNP-KLH 
adsorbed on alum i.p.. Total serum IgE levels 
were measured by an isotype-specific ELISA as 
described previously (Coffman and Carty, 1986). 
TNP-specific IgE was quantitated in a modified 
sandwich ELISA. Plates were coated with the 
same rat monoclonal anti-mouse IgE antibodies 
(EM95, 2 Izg/ml) and incubated overnight at 4°C 
with diluted serum samples. TNP modified with 
alkaline phosphatase (kind gift of Dr. A.J.M. van 
den Eertwegh, MBL-TNO, Rijswijk, Nether- 
lands) was then added. The ELISA was further 
developed using Sigma 104 phosphatase ubstrate 
(Sigma). The detection limit of this ELISA was 
0.2 ng/ml. IL-4, IL-5 and IFN-7 were measured 
by a sandwich ELISA as described previously 
(Schumacher tal., 1988; Cherwinski et al., 1987; 
Chatelain et al., 1992). Hybridoma protein pro- 
duced by encapsulated hybridoma cells was mea- 
sured in a rat IgGl-specific ELISA by coating 
plates with 4/xg/ml of a purified rat IgGl-specific 
mouse monoclonal ntibody Mr G1P (clone MRG 
1; Pharmingen, San Diego, CA) and incubating 
with appropriate dilutions of serum. Subse- 
quently, 0.5 izg/ml of a biotin-conjugated mouse 
anti-rat IgL (K chain) monoclonal ntibody (clone 
MRK 1; Pharmingen), a 1/1000 dilution of a 
streptavidin horseradish peroxidase conjugate 
(Jackson Immunological Laboratory, Westgrove, 
PA) and the substrate 2,2'-azino-bis(3-ethylbenz- 
thiazoline-6-sulphonic a id) (ABTS; Sigma, St. 
Louis, MO) were added. A purified rat IgG1 
(clone R3 34; Pharmingen) was used as an iso- 
type-specific standard. The detection limit of this 
ELISA was 1.25 ng/ml of rat IgG1 in mouse 
serum and there was no cross-reactivity with 
murine IgG1. Substituting the coat with an E. 
coli /3-galactosidase-specific rat IgG1 mAb 
(GLll3) revealed no signal due to idiotypic activ- 
ity. In order to detect rat IgGl-specific immune 
responses in the treated mice, serum dilutions 
were incubated on ELISA plates coated with 4 
/~g/ml of rat IgG1 ( l lBl l ) .  For the detection of 
peroxidase-labelled goat anti-mouse IgM or IgG 
antibodies (Southern Biotechnology Associates, 
Birmingham, AL) were used at a 1/1000 dilution. 
The derived serum concentrations were ex- 
pressed as arithmetic means (+ 1 SD). 
2.6. Reverse type PCR analysis of IL-4 gene expres- 
sion 
Cells were collected and resuspended in 0.5 ml 
of 4 M guanidinium thiocyanate (GTC; Fluka, 
Buchs, Switzerland) and either analysed irectly 
188 H.F.Z Savelkoul et al. /Journal of Immunological Methods 170 (1994) 185-196 
or frozen at -70°C until further analysis. Total 
cellular RNA was isolated after making up the 
volume of the sample to 2.5 ml with GTC accord- 
ing to the method of Chirgwin et al. (1979). 
Gradient centrifugation was performed on an 
equal volume of 5.7 M cesium chloride for 18 h in 
an ultracentrifuge (Sorvall-Du Pont, Newtown, 
CT). After ethanol precipitation, 1 /zg RNA was 
used in a reverse transcriptase r action, modified 
from the procedure of Krug and Berger (1987). 
Briefly, 0.01 U oligo(dT)15 (Pharmacia, Uppsala, 
Sweden) was added to a final volume of 14 /zl 
and both RNA and oligo(dT)15 were heated for 3 
min at 85°C. Then the oligo-primed RNA was 
added to a mixture containing 1 x avian myoblas- 
toma virus reverse transcriptase buffer (50 mM 
Tris-HC1, pH 8.3; 50 mM KCI; 10 mM MgCI2; 1 
mM dithiothreitol; 1 mM EDTA (ethylenedia- 
mine tetraacetate disodium dihydrate salt); 1 
/zg/ml bovine serum albumin), 1 mM deoxy nu- 
cleotide triphosphate (dNTP), 4 mM sodium py- 
rophosphate, 40 U RNAsin (Promega, Madison, 
WI) and 5 U avian myoblastoma virus reverse 
transcriptase (Boehringer Mannheim, Germany). 
This mixture was incubated for 1 h at 39°C. From 
this cDNA mixture 5% was used in a PCR reac- 
tion. To this end, the cDNA was mixed with 
1 x Taq buffer (10 mM Tris-HCl, pH 8.3; 50 mM 
KCI; 1.5 mM MgC12; 0.01% (w/v) gelatin), 0.2 
mM dNTP, sense and anti-sense primers (OD0. 2) 
and 1 U Taq polymerase (Perkin-Elmer Cetus, 
Norwalk, CT). For amplification, 35 cycles (1 min 
at 94°C for denaturation, 2 min at 55°C for an- 
nealing and 3 min at 72°C for primer extension) 
were performed, using a Perkin-Elmer Cetus 
DNA thermal cycler. For all samples, an IL-4 
sense and anti-sense primer set and a sense and 
anti-sense primer set for the HPRT (hypo- 
xanthine phosphatidyl ribosyltransferase) house- 
keeping gene were used. 
2. Z Staining 
Cell suspensions were stained with anti-I-A °
(done 39-10-8, Pharmingen, San Diego, CA) mAb 
as described previously (Knulst et al., 1991). Cells 
were analysed using a flow cytofluorometer 
(FACScan, Becton Dickinson, Mountain View, 
CA). 
3. Results 
3.1. Cytokine transfected cells or hybridoma cells 
can be encapsulated 
Alginate permits the encapsulation of both 
non-adherent hybridoma cells and adherent cy- 
tokine gene transfected cell lines. The latter cells 
can be grown on Cytodex beads and subsequently 
encapsulated in alginate as shown in Fig. 1. The 
difference in the cell source determines the mini- 
mum size of the needle employed in the encapsu- 
lation procedure, namely 25 or 27 gauge for hy- 
Fig. 1. A: photograph s owing beads covered with IL-4 transfected CV1 cells encapsulated in alginate (40 X magnification). B: 
detail of a C3rtodex bead fully covered with CV1/IL-4 cells (100 x magnification). 
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br idoma cells or 23 gauge for cells grown on 
beads (data not shown). The use of beads allows 
the exact dosage of cells implanted in vivo after 
encapsulat ion to be determined,  since cells ad- 
here to the beads only. Ful ly occupied beads 
grown with transfected CV1/ IL -4  cells conta ined 
on the average 500 live cells per  bead as deter-  
mined by Trypan Blue exclusion after str ipping 
the cells by incubat ion for 5 min in trypsin EDTA.  
Using a 23 gauge needle,  capsules comprising, on 
average, five beads per  capsule were obtained.  
This necessitates implantat ion of roughly 4000 
beads per  mouse in order  to administer  2 × 10 6 
cells. 
To allow a sufficient degree of gelat inat ion 
and hardening to occur, the capsules were incu- 
bated for some t ime in a CaCl 2 solution. This 
t reatment  was not detr imenta l  to the viabil ity of 
the encapsulated cells. In order  to determine the 
opt imal  incubat ion time, XMG 1.2 cells were 
encapsulated and the capsules were incubated for 
various per iods in the CaC12 solut ion after which 
Table 1 
Effect on cell viability of hardening of alginate capsules in 
CaCl 2 
Time (min) Viability (%) 
0 82 
1 60 
2 62 
5 50 
10 44 
15 50 
XMG1.2 cells encapsulated in alginate were maintained in 
fresh 80 mM CaCl 2 solution prepared in water. Viability is 
expressed relative to the starting cell population. 
the capsules were dissolved with t ryps in-EDTA.  
The viabil ity of the cells was determined by try- 
pan blue exclusion. The results (Table 1), showed 
that viabil ity dur ing incubat ion t imes of 1 min up 
to 15 min did not differ significantly. In subse- 
quent exper iments the capsules were incubated 
for 10 min. 
RT-PCR analysis of IL-4 expression in alginate encapsulated CV-1 cells 
1 2 3 4 5 6 7 8 9 10 11 
IL-4 
214 bp ---~ 
HPRT 
176 bp ~1~ 
Fig. 2. Alginate ncapsulated CV1/IL-4 cells (2 >< 106) were implanted (i.p.). Capsules were washed out of the peritoneum on the 
days indicated and cells were detached from the beads. Total RNA was extracted, cDNA was prepared and reverse type PCR 
analysis was performed using an IL-4 primer set (A) or HPRT primer set (B). Lane 1: base pair marker (Phi X174 RF DNA 
HaeIII digest); lane 2: mock transfected control; lanes 3-8:CV1/IL-4 cells washed out on days 0, 3, 5, 7, 10 or 14; lane 9: mock 
transfected control; lane 10: positive control (CDC 35 T cell clone); lane 11: bp marker. 
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3.2. Encapsulated cells secrete cytokines or antibod- 
ies in vivo 
The in vivo production of cytokines by encap- 
sulated cytokine-transfected c lls cannot be mea- 
sured in the serum due to the abundant presence 
of inhibitors, such as soluble cytokine receptors. 
Alternatively, despite the fact that cytokine is 
continuously released in vivo at a single time 
point, not enough IL-4 may be present in the 
serum to be detected in our assay. This could be 
the result of a low secretion rate, analogous to 
IL-6 (Shirai et al., 1993). Therefore, we analysed 
the mRNA expression of IL-4 by encapsulated 
CV1/IL-4 cells that were washed out of the 
peritoneal cavity on various days after implanta- 
tion. The results (Fig. 2) show that even up to 14 
days after implantation IL-4 mRNA could still be 
detected. After day 14 the level of expression of 
both IL-4 mRNA and HPRT mRNA slowly de- 
clined suggesting increasing cell death. 
In order to determine whether encapsulated 
hybridoma cells were still able to secrete their 
mAb, 2 x 106 TNP-specific mouse IgE secreting 
IgELA2 hybridoma cells were injected into 
BALB/c mice. Serum analysis of total and TNP- 
specific IgE showed up to a 10-fold increase in 
total IgE level after 6 days due to a 100-fold 
increase in TNP-specific IgE antibodies (Table 
2). The serum IgE level remained elevated for up 
to 32 days, although gradually declining after 14 
days. 
The injected hybridoma ceils carried the H-2 d 
haplotype that is compatible with the haplotype 
Table 2 
TNP-specific IgE levels in the serum of IgELA2 hybridoma- 
bearing mice 
Day IgE (/Lg/ml) Ascites 
Total TNP-specific incidence 
0 1.115:0.42 < 0.005 0/10 
6 4 .29+_1.13 1.44+0.37 0/10 
14 8.45 5:1.69 5.36 + 1.21 2/10 
22 8.63+-1.24 6.54+1.15 6/10 
32 2.86+0.87 1.04+0.17 10/10 
BALB/c mice were implanted i.p. with 2× 106 TNP-specific 
IgELA2 cells encapsulated in alginate. Serum IgE levels, 
expressed in ~g/ml, are arithmetic means+ 1 SD (n = 10). 
10 2 
3 
101 
/ 
10o 
5 10 15 
de, ys 
Fig. 3. Kinetics of clearance of rat IgG1 from mouse serum. 
BALB/c mice were injected with either 1.5 (squares) or 2 mg 
(circles) purified XMG 1.2 mAb or implanted i.p. with 2 × 106 
encapsulated cells (triangles). Serum levels of rat IgG1 were 
monitored by specific ELISA. Results are expressed as means 
(n = 5). 
of the BALB/c mice used. Hence there was 
rapid development of peritoneal tumors accom- 
panied by the formation of ascites fluid. This 
suggests that upon leakage or breaking of the 
alginate capsules, the hybridoma cells are able to 
induce ascites formation. However, as shown in 
Table 2, ascites formation occurred, relatively 
late (more than 14 days) after implantation of 
encapsulated hybridoma cells. 
Repeating the experiment in SJL mice, peri- 
toneal cells were harvested on days 3, 5 and 7 
after implantation and the non-encapsulated c lls 
were stained for the H-2 d haplotype. Subsequent 
FACScan analysis failed to reveal significant 
amounts ( > 5%) of free hybridoma cells (data not 
shown). We therefore assume that leakage of 
actively secreting cells from the capsule is not 
significant. 
3.3. Kinetics of the in vivo production by encapsu- 
lated cells 
To determine the rate at which rat IgG1 ap- 
peared in the serum after implantation of encap- 
sulated hybridoma cells, kinetic experiments were 
performed. As shown in Fig. 3, significant levels 
of rat IgG1 were detected in the serum after 3 
days, peaking around day 8, and lasting for at 
least 13 days. For comparison, mice were injected 
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once with either 1.5 or 2 mg of purified XMG 1.2 
(rat IgG1) antibodies (Fig. 3). In these cases a 
steadily declining serum level of rat IgG1 was 
observed. From the data obtained the rate of 
disappearance ('biological half life') of rat hy- 
bridoma IgG1 in mouse serum in vivo was esti- 
mated to be of the order of 4.5 days. This figure 
was calculated from the data obtained after injec- 
tion of purified hybridoma protein as well as from 
the data obtained after implantation of encapsu- 
lated hybridoma cells. In addition, in the case of 
rat IgG1 production by encapsulated hybridoma 
cells in vivo, the synthetic rate as determined by 
the increase in serum level was estimated to be of 
the order of 1.5 days. As is evident from Fig. 3, 
implantation of 2 x 10 6 encapsulated hybridoma 
cells provided a serum level of rat IgG1 that was 
lower than that obtained by injecting 1.5 mg 
purified IgG1. On the other hand the serum 
levels of rat IgG1 were much more prolonged 
after implantation than after injection of purified 
rat IgG1. Collectively, these results suggest hat 
implantation of alginate encapsulated cytokine 
transfected cells or hybridoma cells provides an 
efficient method for cytokine or antibody treat- 
ment in vivo for periods of up to 14 days. 
3.4. Dose-response titration of encapsulated cells 
In order to determine the amount of hy- 
bridoma protein present in the serum of mice 
implanted with various doses of encapsulated 
cells, dose titrations were performed. To this end, 
encapsulated rat IgGl-secreting hybridoma cells 
specific for the cytokine IL-5 were implanted. 
The appearance of rat IgG1 in the serum of these 
mice was determined by ELISA and the persis- 
tence of this rat Ig was studied. As shown in Fig. 
4A, the injection of 2 × 10 6 encapsulated cells 
resulted in the appearance in the serum of hy- 
bridoma protein at concentrations up to 100 
p.g/ml. These levels were reached after 7 days 
and lasted for up to 21 days, after which they 
steadily declined. A dose of 3 x 10 3 cells resulted 
in a 1000-fold lower serum level of hybridoma 
protein that did not show clear kinetics and was 
at the limit of detection of the ELISA. The other 
doses tested resulted in intermediate serum levels 
of rat IgG1. The maximum increase in rat IgG1 
levels in the serum occurred between days 7 and 
21, suggesting that the implanted cells were still 
actively secreting the hybridoma protein (Fig. 4B). 
3.5. Implantation sites of encapsulated cells 
All of the results described above were ob- 
tained by i.p. implantation of encapsulated cells. 
This site can easily accommodate 1 ml samples. 
Moreover, multiple implantations of I ml samples 
can be performed i.p. when using 2 week inter- 
vals. For applications in which a single implanta- 
tion is to be used the s.c. site may be preferable. 
1C 2 
10, 
10 o 
10-1 . 
5 10 15 20 25 
days 
i 1 day 3~ 
7 days 
• 11 days 
[ ]  14d~ 
V 21 days 
• 28 days 
10' 
10-1. 
103 . . . . .  io, . . . . .  +~, . . . . . . .  i~, 
ce l l  dose 
Fig. 4. Kinetics of cell dose-dependent rat IgG1 production. BALB/c mice were implanted i.p. with encapsulated TRFK 5 cells and 
rat IgG1 production was monitored by ELISA. A: serum levels of hybridoma protein at various intervals after implantation of
alginate ncapsulated cells. Doses of 2 × 10 6 (circles), 8 × 104 (squares) and 3 x 10 3 (triangels) encapsulated TRFK5 cells were 
used. B: serum levels of hybridoma protein at various doses of the alginate ncapsulated cells. Serum levels were determined 1,3, 
7, 11, 14, 21 and 28 days after implantation as indicated. Results are expressed as mean serum levels (n = 5). 
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Fig. 5. Effect of implantation site on the production of hy- 
bridoma protein. BALB/c mice were implanted i.p. (open 
symbols) or s.c. (closed symbols) with 2x10 6 encapsulated 
I lBl l  cells. Rat IgG1 levels were monitored by a specific 
ELISA. Results are expressed as mean serum levels (+ 1 SD) 
(n = 10). 
To analyze efficacy in terms of long term anti- 
body production, both sites of implantat ion were 
compared. To this end, 2 × 10 6 l lB l l  cells were 
encapsulated and implanted either i.p. or s.c.. 
Again, rat IgG1 levels were monitored. Fig. 5 
shows that s.c. implantat ion resulted in signifi- 
cantly higher and more sustained antibody pro- 
duction than i.p. implantation. The s.c. site was 
therefore considered to be superior for single 
implantat ion and cells were found to remain ac- 
tive for periods up to 1 month (data not shown). 
The i.p. site, on the other hand, was found to be 
more suitable for multiple injections (every 14 
days) which permits cytokine or antibody treat- 
ments over prolonged periods of time. 
3.6. Mouse anti-rat response after implantation of 
encapsulated cells 
Since mice can be treated for long periods of 
time with encapsulated hybridoma cells that pro- 
vide low but persistent levels of hybridoma pro- 
tein, a host anti-rat response could be expected 
to occur. In order to investigate the occurrence of 
such a response, BALB/c  mice were immunized 
with 10 mg TNP-KLH on alum i.p. 3 months later 
mice were boosted with a similar dose of antigen. 
Dur ing the whole immunizat ion period the mice 
were treated every other week with 2 × 10 6 en- 
capsulated l lB l l  cells implanted i.p. In total the 
mice received seven repeated injections. As is 
evident from Fig. 6, only a minor rat IgGl-specif ic 
IgM response developed during the booster re- 
sponse. No IgG anti-rat IgG1 response could be 
detected in these mice (data not shown). Moni- 
toring of the serum revealed around 10 /zg /ml  of 
rat IgG1 was present in the mouse serum (data 
not shown). 
Table 3 
Cytokine-dependent modulation of primary IgE responses by encapsulated cells 
Strain TNP-KLH Encapsulated Antibody 
immunization cells treatment 
Anti-TNP IgE (ng/ml) 
Day 0 Day 14 
BALB/c 
SJA/9 
- - - 15 18 
+ - - 20 1947 
+ CHO/IFN-y - 18 21 
+ CHO/IFN-3, XMG1.2 17 2 354 
+ l lBl l  - 32 28 
+ - l lB l l  25 27 
+ Capsules only - 29 32 
+ - - 32 25 
+ CV- 1/IL-4 - 19 2 048 
+ CV-1/IL-4 GL113 19 2123 
+ CV-1/IL-4 11Bll 21 20 
+ CV-1/ILo5 - 16 20 
+ GL113 - 20 29 
Mice were immunized (i.p.) with 10/~g TNP-KLH in alum on day 0. Mice were treated with 2 × 10 6 alginate ncapsulated cells 
implanted i.p. and/or with 2 mg of purified XMG1.2 or GLl13 or 10 mg of 11Bll mAb i.p. Serum levels were determined by 
TNP-specific IgE ELISA. Results are reported as arithmetic means (n = 5). 
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l 
days 
Fig. 6. Mouse anti-rat response after implantation f rat 
IgGl-secreting hybridoma cells. BALB/c mice were im- 
planted with 2× 10 6 encapsulated 11Bll cells i.p. Mouse IgM 
anti-rat IgG1 responses were determined in an ELISA proce- 
dure. Results are expressed asmeans+ 1 SD (n = 5). 
subsequent IgE production could be blocked by 
anti-IL-4, suggesting an IL-4-mediated IgE pro- 
duction. The results in Table 3 also show that 
implanting 2 × 106 l lB l l  or XMG 1.2 hybridoma 
cells resulted in in vivo effects that were at least 
comparable to those obtained by injecting 2 mg of 
XMG 1.2 or even 10 mg of l lB l l  per mouse. 
These doses have been widely shown to be suffi- 
cient to block cytokine mediated effects in vivo. 
Moreover, these results show that injection of 
encapsulated mpty Cytodex beads or IL-5 trans- 
fected CV1 cells did not lead to IgE production 
in SJA/9 mice. 
4. Discussion 
3. 7. Modulation of lgE formation in vivo by encap- 
sulated cells 
In order to test the possibilities of modulating 
in vivo immune responses, e.g., IgE formation, 
mice were immunized and implanted with encap- 
sulated fibroblast cells transfected with cytokine 
genes or hybridoma ceils. IgE high responder 
BALB/c or non-responder SJA/9 mice were im- 
munized with 10/~g TNP-KLH on alum i.p. These 
mice were implanted i.p. with encapsulated CV1 
cells transfected with the IL-4 or the IL-5 gene or 
with CHO ceils transfected with the IFN-y gene. 
Subsequently, these mice were treated with 10 or 
2 mg of purified anti-IL-4 or anti IFN-y mAb i.p. 
respectively, doses widely shown to be sufficient 
to block IL-4 or IFN-y-mediated effects in vivo. 
As an isotype control, mice were treated with 
GLl l3 mAb. The resulting TNP-specific IgE lev- 
els in the serum were analysed by ELISA. As 
Shown in Table 3, the resulting TNP-specific IgE 
response in BALB/c mice could be blocked by 
IFN-y secreting cells, anti-IL-4 secreting cells or 
purified anti-IL-4 mAb. Blocking the activity of 
IFN-y by treatment with purified anti-IFN-y mAb 
resulted in a marked increase in TNP-specific 
IgE to levels higher than those obtained by TNP- 
KLH immunization alone. SJA/9 mice could 
overcome the defective IgE production following 
implantation with IL-4-transfected cells, and the 
This study has shown that alginate ncapsula- 
tion of cytokine transfected cells offers an easy 
way to establish a constant systemic level of cy- 
tokine in vivo for prolonged periods of time. 
Moreover, the use of adherent growing trans- 
fected fibroblasts in combination with Cytodex 
beads provides an exact dosage of implanted cells 
and allows precise dose-response r lationships to 
be defined. Although hybridoma cells can also be 
encapsulated effectively in alginate, growth will 
continue until limited by physical parameters, 
such as charge repulsion between the net nega- 
tive surface of cells and the negatively charged 
carbohydrate groups of the alginate (Haug and 
Smidsrod, 1967). The leakage of entrapped cells 
out of the capsules is undetectable, at least to day 
7. Therefore, cells released from the capsules 
resulting from breaking or dissolving the capsule 
will not remain viable and thus such cells will not 
contribute to the observed serum levels of hy- 
bridoma protein. The maximum numbers of cells 
that can be encapsulated is largely determined by 
the low gel strength of the capsules and by cer- 
tain diffusion restrictions; mainly for oxygen 
(Cheetham et al., 1979). Determination of an 
exact dosage of implanted hybridoma cells is vir- 
tually impossible, since the implanted capsules 
permit further proliferation until limited by phys- 
ical constraints. On the other hand, the activity of 
implanted hybridoma cells can be measured eas- 
ily by monitoring the serum for the presence of 
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the secreted antibodies. As shown here, the rate 
of disappearance of rat IgG1 delivered in this 
way is roughly 4.5 days, which is an estimate of 
the biological half-life and equivalent to the half 
life estimated by the injection of purified rat mAb 
(Wawrzyneczak et al., 1992). Recently, an alter- 
native method was described to deliver some 
cytokines for periods up to 9 days by complexing 
low doses of cytokine with either neutralizing 
antibodies or soluble receptors (Sato et al., 1993). 
A potential problem arising from the implanta- 
tion of hybridoma cells for in vivo antibody pro- 
duction, certainly for anti-cytokine antibodies, is
cytokine production by the hybridoma cells them- 
selves. As has been described, hybridoma cells 
can secrete relatively large amounts of IL-6 and 
although in this study rat hybridomas were used 
in mice, there can be sufficient cross-reactivity to 
induce interfering unknown bystander effects 
(Van Damme et al., 1987). 
As shown here, the implanted capsules tay 
intact and the cells continue to secrete their 
cytokine for up to 3 weeks. Furthermore, using an 
ELISA specific for soluble mouse-anti-rat IgG1 
antibodies does not reveal a detectable anti-rat 
response in the host triggered by encapsulated 
ceils. The ELISA employed, however, would not 
be able to detect anti-rat antibodies complexed to 
the rat hybridoma protein. Such complexes could 
consist of anti-isotypic antibodies or anti-idiotypic 
antibodies pecific for rat IgG1. The use of an 
irrelevant rat IgG1 for coating did not reveal any 
signal in the serum of treated mice, suggesting 
that either large complexes are formed (due to 
anti-isotypic antibodies) in the serum or substan- 
tial amounts of anti-idiotypic antibodies are pre- 
sent that cannot be detected. The serum levels of 
rat IgG delivered by alginate encapsulated hy- 
bridomas were relatively low (mostly _< 25 /zg/ 
ml), and this IgG was only induced in the absence 
of an adjuvant. Although the serum level of rat Ig 
was sufficient o block the specific ELISA, we 
consider the induction of an anti-rat Ig response 
unlikely within the limitations of our detection 
technique. Moreover, the decrease in serum lev- 
els of rat IgG1 after 14 days was reflected in the 
parallel deterioration of the alginate capsules and 
the increased death of hybridoma cells. This 
makes it unlikely that a mouse anti-rat response 
(both idiotypic and isotypic) would be responsible 
for the decrease in rat IgG serum levels. 
Complexes of cytokines with anti-cytokines 
have been shown to increase the half life of 
cytokines in the serum (Sato et al., 1993). Anti-cy- 
tokine antibodies (delivered by alginate capsules) 
should be active in their depleting capacity for 
periods of more than 2 weeks but this has not 
been observed. Moreover, the injection of rat 
purified IgG1 antibodies did not induce an anti- 
rat immune response despite the initial high doses 
of antibody present. Since no adjuvant was used, 
the serum half life of 4.5 days ensured a rapid 
decline to levels comparable to those in alginate 
implanted mice. In another study (Van Ommen 
et al., submitted) mice were treated at bi-weekly 
intervals with 10 mg purified l lB l l  per mouse 
for a period of 3 months. In these mice no 
significant rat IgGl-specific IgG response could 
be detected uring this treatment and the rat 
IgG1 serum levels never exceeded 25 ~g/ml. 
This makes it unlikely that an induced immune 
response would be missed using the ELISA. When 
other anti-mouse cytokine rat IgG mAbs were 
used, anti-rat IgG1 responses were not detected. 
This was probably due to the fast clearance of 
both uncomplexed and cytokine-complexed anti- 
bodies. 
A medium for the entrapment of living cells 
should cause as little trauma to the ceils as possi- 
ble. There should, ideally, be no shock to the 
cells from change of temperature, chemical envi- 
ronment and osmotic pressure. Entrapment in 
calcium alginate meets all these criteria. Algi- 
nate, extracted with sodium hydroxide from 
Macrocystis pyrifera, consists of a copolymer of 
/3-D-mannopyranosyl uronate and a-L-gulopyra- 
nosyl uronate linked by (1 ~ 4)-glycosidic link- 
ages. When exposed to divalent ions such as 
Ca 2 +, an inert three-dimensional po ymer gel net- 
work is formed with relatively large intercon- 
nected interstitial spaces (Bucke, 1987). The aver- 
age diameter of the capsules (approximately 0.5-5 
ram), is limited by the size of the needle and the 
pressure applied to the syringe. The main disad- 
vantages of alginate capsules are (1) they are 
rapidly disrupted by chemicals capable of chelat- 
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ing calcium ions, and (2) the potential imitation 
of oxygen transfer into the capsule (Familetti and 
Fredericks, 1988; Hashimoto and Shirai, 1990). 
When comparing various implanted hybridoma 
cells, it appears that at maximum production these 
cells yield systemic levels of 10-100/zg /ml  of rat 
IgG. This points to a limited production poten- 
tial, possibly due to a lack of oxygen or reduced 
diffusion of nutrients and waste products. 
IgE responses are dependent on the presence 
and activity of functional IL-4 as the most promi- 
nent IgE switch inducing factor. IFN-y, being a 
major antagonist of IL-4, plays an important role 
in the downregulation of the IgE production 
(Finkelman et al., 1988; Mosmann and Coffman, 
1989a). It has been suggested that the ratio of 
IL-4 to IFN-y determines the ability to produce 
IgE in vivo (Snapper and Paul, 1987; Mosmann 
and Coffman, 1989b). Thus, implantation in IgE 
high-responder BALB/c  mice of either cytokine 
transfected cells or hybridoma cells provides an 
effective model system to modulate the IgE re- 
sponse based on influencing the balance between 
essential cytokines in vivo. As is evident from the 
results (Table 3), the IgE response induced by 
immunization with TNP-KLH can effectively be 
inhibited by implantation of IFN-3, producing 
CHO/ IFN-y  cells. Subsequent neutralization 
with purified anti- IFN-y mAb (XMG 1.2) in- 
duced complete reversal of this inhibition. Im- 
plantation of anti-IL-4 secreting hybridoma cells 
(11Bll)  or injection of purified anti-IL-4 mAb 
resulted in a similar degree of inhibition to that 
observed with implanted CHO/ IFN-y  cells. 
These findings are in complete agreement with 
the hypothesis that the relative amounts of func- 
tional IL-4 and IFN-y are sufficient o determine 
the IgE response in vitro. IgE non-responder 
S JA /9  mice, on the other hand, do not react to 
TNP-KLH immunization with the formation of 
TNP-specific IgE. Following infection with the 
helminth parasite Nippostrongylus brasiliensis it 
has previously been shown that implantation of 
alginate ncapsulated CV-1/ IL-4 transfected cells 
was able to restore IgE formation to levels com- 
parable to those in BALB/c  mice (Savelkoul et 
al., 1991). Here, we were able to show that a 
similar treatment restored the formation of 
TNP-specific IgE. This S JA /9  model clearly 
shows that implantation of CV-1/ IL-4 cells yields 
sufficient functional IL-4 to induce the formation 
of IgE. Collectively, these results illustrate the 
potential applicability of implantation of alginate 
encapsulated cytokine transfected cells in the 
modulation of immune responses in vivo. 
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